Ventyx Biosciences is a clinical-stage biopharmaceutical company that specializes in developing innovative oral medicines for patients with autoimmune and inflammatory disorders. With a strong focus on addressing unmet medical needs, our goal is to offer novel oral therapies that shift the immunology markets from injectables to oral drugs. Our pipeline consists of four clinical-stage programs targeting TYK2, S1P1R, and NLRP3, and we are poised to become leaders in the development of oral immunology drugs.

Led by experienced leaders in the discovery and development of immunology drugs, such as our Founder, CEO, and Director, Raju Mohan, PhD, Ventyx Biosciences has a proven track record of success. Dr. Mohan previously founded Akarna Therapeutics, which was acquired by Allergan for up to $1.

2B, and has also founded other immunology-focused specialty pharmaceutical companies. At Ventyx Biosciences, we are committed to developing novel medicines that provide effective treatment options for autoimmune and inflammatory diseases